BioSpace News Archive

Opthea Limited announced that Dr. Megan Baldwin, the Company’s Chief Executive Officer will present at the 2023 Opthalmology Innovation Summit being held in Seattle, WA on July 27th, 2023.

Immuron Limited, an Australian based and globally integrated biopharmaceutical company is pleased to advise our Chief Executive Officer, Steven Lydeamore will be presenting at the 17th Bioshares Biotech Summit in Hobart, Australia on July 24th.

Belite Bio, Inc announced that enrollment of its pivotal global Phase 3 “DRAGON” trial for patients with Stargardt Disease has completed.

Theravance Biopharma, Inc. will report its second quarter 2023 financial results and provide a business update after market close on Monday, August 7, 2023.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus on lung disease, announced that it will release financial results for the second quarter ended June 30, 2023 after the close of trading on Monday, August 7.

ImmunoGen, Inc. announced a multi-target license and option agreement to research novel, first-in-class ADCs with ImmunoBiochem Corporation, a privately-held biopharmaceutical company focused on the discovery of unique tumor targets and development of novel biological therapeutics.

Eagle Pharmaceuticals, Inc. announced that the first patient has been randomized in its multi-center adaptive, randomized, double-blind, placebo-controlled Phase 2 study designed to assess the efficacy and safety of CAL02 administered intravenously in addition to standard of care in patients with severe community-acquired bacterial pneumonia.

BioNTech SE will announce its financial results for the second quarter 2023 on Monday, August 7th, 2023.

ImmunoBiochem Corporation announced a multi-target license and option agreement with ImmunoGen, Inc., a leader in the expanding field of antibody-drug conjugates, to advance novel, first-in-class ADCs.

BD Chairman, CEO and President Tom Polen issued the following message regarding the U.S. Food and Drug Administration 510 clearance for the updated BD Alaris™ Infusion System:.